At Piedmont Eye Center we are dedicated to our patients and providing the latest technology available. To ensure technology continues to advance, we participate in many clinical trials. Subjects are compensated for time and travel and participation is without cost to the patient.
If you would like more information about specific studies, please fill out the form below the list of current studies.
Current Studies
AGE-RELATED MACULAR DEGENERATION (AMD)- Open Enrollment
SPONSOR: Janssen Research & Development, LLC
BRIEF SUMMARY: The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
SPONSOR: Genentech, Inc.
BRIEF SUMMARY: Study ML43000 is a Phase IV multicenter, open-label (BCVA assessor-masked) study designed to assess the response to treatment with SUSVIMO Q24W in patients with nAMD who have been previously treated with anti-VEGF agents other than ranibizumab. The substudy will evaluate the impact on corneal endothelial cells with SUSVIMO refilled every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).
SPONSOR: OPTHEA LTD.
Objective: To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 0.5 mg ranibizumab, in participants with neovascular AMD.
DIABETES- Open Enrollment
SPONSOR: Oxurion
BRIEF SUMMARY: Part A of the study is conducted to select the THR-149 dose level.
Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3. As from Month 3, in about half of the subjects, the effect of a single flip-over injection (aflibercept or THR-149) will be evaluated when administered 1 month after the 3 monthly injections of THR-149 or aflibercept. In the other subjects, the durability of 3 monthly injections of THR 149 or aflibercept will be evaluated.
SPONSOR: HOFFMAN-LA Roche
Primary Purpose: Treatment
SPONSOR: GENENTECH, INC.
Primary Purpose: Treatment
DRY EYE- Open Enrollment
GLAUCOMA- Open Enrollment
Title: A Phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect after Single Administration of PER-001 Intravitreal Implant in Participants with Open-Angle Glaucoma (Perfuse)
Sponsor: Perfuse Therapeutics, Inc.
Brief Summary: The purpose of this research study is to see if PER-001 Intravitreal Implant is safe and tolerable. It is planned that up to 12 people with glaucoma will be in Stage 1 and approximately 24 people with glaucoma in Stage 2 of this study. An additional 30 people with glaucoma may be enrolled in Stage 2.
Sponsor: Laboratories Thea
Brief Summary: The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
PRESBYOPIA- Open Enrollment
Sponsor: Visus Therapeutics
Purpose: Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia
REFRACTIVE- Open Enrollment
Title: QAD-079 GoEyes
Sponsor: 1-800-CONTACTS
Brief Summary: A prospective, multicenter, open label study to evaluate the reliability, validity, and safety of subjective mobile refraction assessed by GoEyes.
ATOPIC KERATOCONJUNCTIVITIS- Open Enrollment
OPEN STUDIES-CLOSED ENROLLMENT
TITLE: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
SPONSOR: AbbVie
BRIEF SUMMARY: This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Title: A Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Sponsor: Aerie Pharmaceuticals
Brief Summary: This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit)
TITLE: OTT166 in Diabetic Retinopathy (DR)
SPONSOR: OcuTerra Therapeutics, Inc
BRIEF SUMMARY: This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
SPONSOR: Alexion Pharmaceuticals
BRIEF SUMMARY: This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
SPONSOR: IONIS
Objective: To evaluate the effect of ISIS 696844 on the rate of change of the area of GA secondary to AMD measured by fundus autofluorescence (FAF) Secondary Objectives To evaluate the effect of ISIS 696844 on plasma FB levels and serum AH50 activity in AMD patients To assess the effect of ISIS 696844 to slow reduction of low luminance visual acuity (LLVA).
TITLE: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
SPONSOR: EyePoint Pharmaceuticals, Inc
BRIEF SUMMARY: This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.
Sponsor: AbbVie ( formerly Allergan)
Purpose: This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
SPONSOR: Oculis
BRIEF SUMMARY: The purpose of this study is to evaluate the efficacy and safety of OCS-01 Ophthalmic Suspension versus placebo (vehicle) in the treatment of inflammation and pain following cataract surgery.
SPONSOR: Hoffmann-La Roche
BRIEF SUMMARY: This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.
SPONSOR: OCULIS
BRIEF SUMMARY: The purpose of this study is to evaluate the efficacy and safety of OCS-01 ophthalmic suspension versus vehicle alone in subjects with DME.
Title: A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 (COMET-4)
Sponsor: Aerie Pharmaceuticals
Brief Summary: This will be a 12-month, multicenter, vehicle-controlled, double-masked, randomized Phase 3 study conducted at approximately 10 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of a Baseline (Day 1) visit as well as visits at Day 14, Day 90, Day 180, Day 270, and Day 365 (Study Exit).
SPONSOR: Kodiac Sciences, Inc.
Objective: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
Sponsor: GLAUKOS CORPORATION
Purpose: To compare the safety and initial efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, USP, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
SPONSOR: F. HOFFMANN-LA ROCHE LTD
Objective: This study will evaluate the long-term safety and tolerability of intravitreal (IVT) faricimab in patients with neovascular age-related macular degeneration (nAMD) who have completed either of the Phase III (GR40306 or GR40844) studies. Additional assessments relating to efficacy, pharmacokinetics, immunogenicity, and biomarkers will be performed.
Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
Sponsor: F. Hoffman-La Roche Ltd.
Purpose: To evaluate the efficacy, safety, and pharmacokinetics of Ranibizumab delivered via the Port Delivery System in patients with Diabetic Retinopathy.
Sponsor: F. Hoffman-La Roche Ltd.
Purpose: Evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab in patients with Diabetic Macular Edema (DME).
Sponsor: GLAUKOS CORPORATION
Purpose: To compare the safety and initial efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, USP, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
SPONSOR: Kodiac Sciences, Inc.
Objective: This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with treatment-naïve DME. The primary endpoint will be assessed at Year 1; additional secondary endpoints for efficacy will be assessed at Years 1 and 2.